Court Grants Teva-Ivax Bid For Zocor Exclusivity

Law360, New York (May 1, 2006, 12:00 AM EDT) -- In a boon for Israeli generics maker Teva Pharmaceuticals Ltd., a federal court has ruled that its recent acquisition, Ivax Corp., should be granted 180 days of exclusivity to market a generic version of Merck & Co.’s blockbuster cholesterol drug Zocor.

Teva confirmed on Monday that it had been granted summary judgment by the U.S. District Court for the District of Columbia, triggering hopes that Ivax will finally win exclusivity following a six-year crusade to sell generic Zocor.

The development serves as welcome news for Teva,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.